SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 11,650.40 |
| Enterprise Value ($M) | 11,466.65 |
| Book Value ($M) | 2,131.02 |
| Book Value / Share | 7.75 |
| Price / Book | 5.47 |
| NCAV ($M) | 690.28 |
| NCAV / Share | 2.51 |
| Price / NCAV | 16.88 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.27 |
| Return on Assets (ROA) | 0.23 |
| Return on Equity (ROE) | 0.30 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 3.44 |
| Current Ratio | 3.50 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 1,396.50 |
| Assets | 2,837.25 |
| Liabilities | 706.22 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 2,168.70 |
| Operating Income | 689.95 |
| Net Income | 521.27 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 699.97 |
| Cash from Investing | -116.78 |
| Cash from Financing | -628.81 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | Farallon Capital Partners, L.P. | 6.80 | -20.50 | |
| 13G/A | BlackRock, Inc. | 10.20 | -20.87 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 429,105 | 1,642,880 | 26.12 | |
| 240,936 | 1,397,088 | 17.25 | |
| 434,759 | 2,247,736 | 19.34 | |
| 419,475 | 2,410,290 | 17.40 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ENTA – Enanta Pharmaceuticals, Inc. | ERAS – Erasca, Inc. |
| EWTX – Edgewise Therapeutics, Inc. | FDMT – 4D Molecular Therapeutics, Inc. |
| FGEN – FibroGen, Inc. |